---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-272936"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:30:44.957239+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enanta reports positive Phase 2 data for zelicapavir in pediatric RSV: 1.4 log viral load drop at Day 5

## Summary
- Part 2 primary endpoint: 1.4 log viral load decline at Day 5 vs placebo (n=34 zelicapavir, n=10 placebo).
- Prespecified early-treatment subset (within 3 days of symptom onset): 1.2 log decline at Day 5 vs placebo.
- 96 patients (70 zelicapavir, 26 placebo) aged 28 days to 36 months; no AEs leading to discontinuation.
- Dose selected: 5 mg/kg for ≥28 days to <12 months; 7.5 mg/kg for ≥12 to ≤36 months.
- Symptom tool RESOLVE-P showed trend toward reduction but data available for only 15 patients.

## SEC filing metadata
- accession: 0001193125-24-272936
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312524272936/0001193125-24-272936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312524272936/d706648d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-272936
- JSON: https://secwatch.observer/filing/0001193125-24-272936.json
- Plain text: https://secwatch.observer/filing/0001193125-24-272936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.